171 related articles for article (PubMed ID: 38596684)
1. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
Chen J; Sun S; Li H; Cai X; Wan C
Front Immunol; 2024; 15():1373321. PubMed ID: 38596684
[TBL] [Abstract][Full Text] [Related]
2. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
3. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
5. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
[TBL] [Abstract][Full Text] [Related]
6. CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Liu YC; Lin YH; Chi HC; Huang PS; Liao CJ; Liou YS; Lin CC; Yu CJ; Yeh CT; Huang YH; Lin KH
Clin Epigenetics; 2022 Aug; 14(1):106. PubMed ID: 35999564
[TBL] [Abstract][Full Text] [Related]
7. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity.
Wang X; Hu R; Song Z; Zhao H; Pan Z; Feng Y; Yu Y; Han Q; Zhang J
Cancer Lett; 2022 Oct; 547():215880. PubMed ID: 35981569
[TBL] [Abstract][Full Text] [Related]
9. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.
Lee S; Lee M; Kim JB; Jo A; Cho EJ; Yu SJ; Lee JH; Yoon JH; Kim YJ
Biochem Biophys Res Commun; 2016 May; 473(4):1247-1254. PubMed ID: 27091428
[TBL] [Abstract][Full Text] [Related]
10. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
11. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma.
Yin Z; Ma T; Lin Y; Lu X; Zhang C; Chen S; Jian Z
J Cell Biochem; 2018 Nov; 119(11):9419-9432. PubMed ID: 30015355
[TBL] [Abstract][Full Text] [Related]
12. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
13. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
[TBL] [Abstract][Full Text] [Related]
15. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma.
Jiang C; Long J; Liu B; Xu M; Wang W; Xie X; Wang X; Kuang M
J Exp Clin Cancer Res; 2017 Jul; 36(1):99. PubMed ID: 28750679
[TBL] [Abstract][Full Text] [Related]
16. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
17. LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells.
Liu Y; Chen L; Yuan H; Guo S; Wu G
Onco Targets Ther; 2020; 13():1145-1157. PubMed ID: 32103983
[TBL] [Abstract][Full Text] [Related]
18. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.
Ding H; Zhang X; Su Y; Jia C; Dai C
Cell Mol Biol Lett; 2020; 25():8. PubMed ID: 32123532
[TBL] [Abstract][Full Text] [Related]
19. Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.
Xiang X; Deng L; Xiong R; Xiao D; Chen Z; Yang F; Liu K; Feng G
Cell Cycle; 2018; 17(11):1310-1318. PubMed ID: 30045663
[TBL] [Abstract][Full Text] [Related]
20. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
